The aim of this project was to identify different perinatal risk indicators and to develop prediction models for neurologic morbidity at 2 and 5 years of age.
A revolutionary approach for the creation of patient-specific human cellular models for neurologic and neurodevelopmental disorders has been developed in 2007 when Yamanaka and colleagues demonstrated that adult somatic cells can be reverted to induced Pluripotent Stem (iPS) cells, an immature status analogous to embryonic stem cells.
In the full multivariate model (adjusted for neurologic treatment status), we found a distinct separation between the hemispheres; for the total population, we estimated the median time to relapse was 29.2 weeks (95% CI 25.0 33.4) and the 95th percentile was 61.4 weeks (95% CI 35.7 87.1).
Results of the unadjusted Kaplan-Meier and parametric models, adjusted for neurologic treatment status in the full dataset, also indicate much longer median times to relapse: 20 weeks (95% CI 9 26) and 10.5 weeks (95% CI 3.7 17.4), respectively.
In the full multivariate model, after adjustment for neurologic treatment status, the median parametric survival estimate for the entire population was 13.6 days (95% CI 12.4 14.7).
This may serve as a model for other chronic neurologic conditions with potential biographic impact.
Nout, Y.S. et al. Animal models of neurologic disorders: a nonhuman primate model of spinal cord injury.
Such methods will facilitate the study of white matter pathology in canine models of neurologic disease.
Stanford Memory Disorders Center offers a 1 year United Council for Neurologic Subspecialties (UCNS) approved Fellowship in Behavioral Neurology.
Characterizing dopaminergic neuronal development and function in novel genetic animal models might uncover strategies for researchers to develop disease-modifying treatments for neurologic disorders.
